Constrained H-Phe-Phe-NH2 analogues with high affinity to the substance P 1-7 binding site and with improved metabolic stability and cell permeability

Journal of Medicinal Chemistry

Volumn 56, Issue 12, 2013, Pages 4953-4965

  Fransson, Rebecca ^a   Sköld, Christian ^a   Kratz, Jadel M ^a,b   Svensson, Richard ^a   Artursson, Per ^a   Nyberg, Fred ^a   Hallberg, Mathias ^a   Sandström, Anja ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTROMETHORPHAN; MIDAZOLAM; PEPTIDE TRANSPORTER 1; PYRROLIDINE DERIVATIVE; SUBSTANCE P [1-7]; SUBSTANCE P DERIVATIVE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE EPITHELIUM; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; PROTEIN METHYLATION; PROTEIN STABILITY; STRUCTURE ACTIVITY RELATION;

BINDING SITES; DIPEPTIDES; DRUG STABILITY; HUMANS; MODELS, MOLECULAR; PEPTIDE FRAGMENTS; PERMEABILITY; PROTEIN BINDING; PROTEIN CONFORMATION; SUBSTANCE P;

EID: 84879571004     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400209h     Document Type: Article

References (52)

1. Von Euler, U. S.; Gaddum, J. H. An unidentified depressor substance in certain tissue extracts J. Physiol. 1931, 72, 74-87
2. Nakanishi, S. Mammalian tachykinin receptors Annu. Rev. Neurosci. 1991, 14, 123-136
3. Hökfelt, T.; Pernow, B.; Wahren, J. Substance P: a pioneer amongst neuropeptides J. Intern. Med. 2001, 249, 27-40
4. Lee, C.-M.; Sandberg, B. E. B.; Hanley, M. R.; Iversen, L. L. Purification and characterization of a membrane-bound substance P-degrading enzyme from human brain Eur. J. Biochem. 1981, 114, 315-327
5. Sakurada, T.; Le Greves, P.; Stewart, J.; Terenius, L. Measurement of substance P metabolites in rat CNS J. Neurochem. 1985, 44, 718-722
6. Hallberg, M.; Nyberg, F. Neuropeptide conversion to bioactive fragments-an important pathway in neuromodulation Curr. Protein Pept. Sci. 2003, 4, 31-44
7. Kreeger, J. S.; Larson, A. A. Substance P-(1-7), a substance P metabolite, inhibits withdrawal jumping in morphine-dependent mice Eur. J. Pharmacol. 1993, 238, 111-115
8. 1-7 attenuates the expression of naloxone-precipitated withdrawal in morphine dependent rats Peptides 2009, 30, 2418-2422
9. Zhou, Q.; Frändberg, P.-A.; Kindlundh, A. M. S.; Le Greves, P.; Nyberg, F. Substance P(1-7) affects the expression of dopamine D2 receptor mRNA in male rat brain during morphine withdrawal Peptides 2003, 24, 147-153
10. Wiktelius, D.; Khalil, Z.; Nyberg, F. Modulation of peripheral inflammation by the substance P N-terminal metabolite substance P1-7 Peptides 2006, 27, 1490-1497
11. Sakurada, C.; Watanabe, C.; Sakurada, T. Occurrence of substance P(1-7) in the metabolism of substance P and its antinociceptive activity at the mouse spinal cord level Methods Find. Exp. Clin. Pharmacol. 2004, 26, 171-176
12. Carlsson, A.; Ohsawa, M.; Hallberg, M.; Nyberg, F.; Kamei, J. Substance P1-7 induces antihyperalgesia in diabetic mice through a mechanism involving the naloxone-sensitive sigma receptors Eur. J. Pharmacol. 2010, 626, 250-255
13. Dyck, P. J.; Dyck, P. J. B.; Velosa, J. A.; Larson, T. S.; O'Brien, P. C.; Grp, N. G. F. S. Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy. A study of three cohorts Diabetes Care 2000, 23, 510-517
14. Skilling, S. R.; Smullin, D. H.; Larson, A. A. Differential-effects of C-terminal and N-terminal substance-P metabolites on the release of amino-acid neurotransmitters from the spinal-cord. Potential role in nociception J. Neurosci. 1990, 10, 1309-1318
15. Mousseau, D. D.; Sun, X. F.; Larson, A. A. Identification of a novel receptor mediating substance-P-induced behavior in the mouse Eur. J. Pharmacol. 1992, 217, 197-201
16. Igwe, O. J.; Kim, D. C.; Seybold, V. S.; Larson, A. A. Specific binding of substance P aminoterminal heptapeptide [SP(1-7)] to mouse brain and spinal cord membranes J. Neurosci. 1990, 10, 3653-3663
17. Botros, M.; Hallberg, M.; Johansson, T.; Zhou, Q.; Lindeberg, G.; Frändberg, P.-A.; Toemboely, C.; Toth, G.; Le Greves, P.; Nyberg, F. Endomorphin-1 and endomorphin-2 differentially interact with specific binding sites for substance P (SP) aminoterminal SP1-7 in the rat spinal cord Peptides 2006, 27, 753-759
18. Botros, M.; Johansson, T.; Zhou, Q.; Lindeberg, G.; Tomboly, C.; Toth, G.; Le Greves, P.; Nyberg, F.; Hallberg, M. Endomorphins interact with the substance P (SP) aminoterminal SP1-7 binding in the ventral tegmental area of the rat brain Peptides 2008, 29, 1820-1824
19. Rimon, R.; Legreves, P.; Nyberg, F.; Heikkila, L.; Salmela, L.; Terenius, L. Elevation of substance P-like peptides in the CSF of psychiatric-patients Biol. Psychiatry 1984, 19, 509-516
20. Nyberg, F.; Le Greves, P.; Sundqvist, C.; Terenius, L. Characterization of substance P(1-7) and (1-8) generating enzyme in human cerebrospinal fluid Biochem. Biophys. Res. Commun. 1984, 125, 244-250
21. Fransson, R.; Botros, M.; Nyberg, F.; Lindeberg, G.; Sandström, A.; Hallberg, M. Small peptides mimicking substance P (1-7) and encompassing a C-terminal amide functionality Neuropeptides 2008, 42, 31-37
22. 1-7 amide on nociceptive threshold in diabetic mice Peptides 2011, 32, 93-98
23. Fransson, R.; Botros, M.; Sköld, C.; Nyberg, F.; Lindeberg, G.; Hallberg, M.; Sandström, A. Discovery of dipeptides with high affinity to the specific binding site for substance P1-7 J. Med. Chem. 2010, 53, 2383-2389
24. Ohsawa, M.; Carlsson, A.; Asato, M.; Koizumi, T.; Nakanishi, Y.; Fransson, R.; Sandström, A.; Hallberg, M.; Nyberg, F.; Kamei, J. The dipeptide Phe-Phe amide attenuates signs of hyperalgesia, allodynia and nociception in diabetic mice using a mechanism involving the sigma receptor system Mol. Pain 2011, 7 (85) 1-12
25. Houston, J. B. Utility of in-vitro drug-metabolism data in predicting in-vivo metabolic-clearance Biochem. Pharmacol. 1994, 47, 1469-1479
26. Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes Drug Metab. Dispos. 1999, 27, 1350-1359
27. Baranczewski, P.; Stanczak, A.; Sundberg, K.; Svensson, R.; Wallin, A.; Jansson, J.; Garberg, P.; Postlind, H. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development Pharmacol. Rep. 2006, 58, 453-472
28. Hubatsch, I.; Ragnarsson, E. G. E.; Artursson, P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers Nat. Protoc. 2007, 2, 2111-2119
29. Bergström, C. A. S.; Strafford, M.; Lazorova, L.; Avdeef, A.; Luthman, K.; Artursson, P. Absorption classification of oral drugs based on molecular surface properties J. Med. Chem. 2003, 46, 558-570
30. Phase, version 3.1; Schrödinger, LLC: New York, NY, 2009.
31. Piercey, M. F.; Dobry, P. J. K.; Einspahr, F. J.; Schroeder, L. A.; Masiques, N. Use of substance-P fragments to differentiate substance-P receptors of different tissues Regul. Pept. 1982, 3, 337-349
32. Huston, J. P.; Hasenoehrl, R. U.; Boix, F.; Gerhardt, P.; Schwarting, R. K. W. Sequence-specific effects of neurokinin substance P on memory, reinforcement, and brain dopamine activity Psychopharmacology 1993, 112, 147-162
33. Tomaz, C.; Silva, A. C.; Nogueira, P. J. Long-lasting mnemotropic effect of substance P and its N-terminal fragment (SP1-7) on avoidance learning Braz. J. Med. Biol. Res. 1997, 30, 231-233
34. Rizo, J.; Gierasch, L. M. Constrained peptides: models of bioactive peptides and protein substructures Annu. Rev. Biochem. 1992, 61, 387-418
35. Turk, J.; Panse, G. T.; Marshall, G. R. alpha-Methyl amino acids. Resolution and amino protection J. Org. Chem. 1975, 40, 953-955
36. Boyle, S.; Guard, S.; Higginbottom, M.; Horwell, D. C.; Howson, W.; McKnight, A.; Martin, K.; Pritchard, M. C.; O'Toole, J. Rational design of high affinity tachykinin NK1 receptor antagonists Bioorg. Med. Chem. 1994, 2, 357-370
37. Haskell-Luevano, C.; Toth, K.; Boteju, L.; Job, C.; Castrucci, A. M. D.; Hadley, M. E.; Hruby, V. J. beta-Methylation of the Phe(7) and Trp(9) melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biological activity J. Med. Chem. 1997, 40, 2740-2749
38. Brandsch, M. Transport of drugs by proton-coupled peptide transporters: pearls and pitfalls Expert Opin. Drug Metab. 2009, 5, 887-905
39. Brodin, B.; Nielsen, C. U.; Steffansen, B.; Frokjaer, S. Transport of peptidomimetic drugs by the intestinal di/tri-peptide transporter, PepT1 Pharmacol. Toxicol. 2002, 90, 285-296
40. Bailey, P. D.; Boyd, C. A. R.; Bronk, J. R.; Collier, I. D.; Meredith, D.; Morgan, K. M.; Temple, C. S. How to make drugs orally active: a substrate template for peptide transporter PepT1 Angew. Chem., Int. Ed. 2000, 39, 505-508
41. Rubio-Aliaga, I.; Daniel, H. Mammalian peptide transporters as targets for drug delivery Trends Pharmacol. Sci. 2002, 23, 434-440
42. VaÌŠbenö, J.; Lejon, T.; Nielsen, C. U.; Steffansen, B.; Chen, W. Q.; Hui, O. Y.; Borchardt, R. T.; Luthman, K. Phe-Gly dipeptidomimetics designed for the di-/tripeptide transporters PEPT1 and PEPT2: synthesis and biological investigations J. Med. Chem. 2004, 47, 1060-1069
43. Vig, B. S.; Stouch, T. R.; Timoszyk, J. K.; Quan, Y.; Wall, D. A.; Smith, R. L.; Faria, T. N. Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding J. Med. Chem. 2006, 49, 3636-3644
44. Gupta, D.; Gupta, S. V.; Lee, K. D.; Amidon, G. L. Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers Mol. Pharmaceutics 2009, 6, 1604-1611
45. Tehler, U.; Nelson, C. H.; Peterson, L. W.; Provoda, C. J.; Hilfinger, J. M.; Lee, K. D.; McKenna, C. E.; Amidon, G. L. Puromycin-sensitive aminopeptidase: an antiviral prodrug activating enzyme Antiviral Res. 2010, 85, 482-489
46. Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L. R.; Chu, X. Y.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek-Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development Nat. Rev. Drug Discovery 2010, 9, 215-236
47. Polli, J. W.; Wring, S. A.; Humphreys, J. E.; Huang, L. Y.; Morgan, J. B.; Webster, L. O.; Serabjit-Singh, C. S. Rational use of in vitro P-glycoprotein assays in drug discovery J. Pharmacol. Exp. Ther. 2001, 299, 620-628
48. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the Folin phenol reagent J. Biol. Chem. 1951, 193, 265-275
49. Maestro, version 9.0; Schrödinger, LLC: New York, NY, 2009.
50. Kaminski, G. A.; Friesner, R. A.; Tirado-Rives, J.; Jorgensen, W. L. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides J. Phys. Chem. B 2001, 105, 6474-6487
51. Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical treatment of solvation for molecular mechanics and dynamics J. Am. Chem. Soc. 1990, 112, 6127-6129
52. Tavelin, S.; Gråsjö, J.; Taipalensuu, J.; Ocklind, G.; Artursson, P. Applications of epithelial cell culture in studies of drug transport Methods Mol. Biol. 2002, 188, 233-272